Highlights
December 22, 2010 – Elizabeth Whittington
Resources
December 22, 2010
Details of Nipple Sparing
December 22, 2010
Under Reconstruction
December 22, 2010 – Diane Lore
Getting to the Core
December 22, 2010 – Elizabeth Whittington
Guiding the Use of Partial-Breast Radiation
December 22, 2010 – Kathy LaTour
New Era for Radiation
December 22, 2010 – Kathy LaTour
Limiting Lymphedema
December 22, 2010 – Kathy LaTour
When Less is Best in Breast Surgery
December 22, 2010 – Laura Beil
Editor's Page
December 22, 2010 – Debu Tripathy, MD
New Drugs, New Direction
January 05, 2011 – Elaine Schattner, MD
Highlights
December 22, 2010 – Elizabeth Whittington
Resources
December 22, 2010
Details of Nipple Sparing
December 22, 2010
Under Reconstruction
December 22, 2010 – Diane Lore
Getting to the Core
December 22, 2010 – Elizabeth Whittington
Currently Viewing
Guiding the Use of Partial-Breast Radiation
December 22, 2010 – Kathy LaTour
Limiting Lymphedema
December 22, 2010 – Kathy LaTour
When Less is Best in Breast Surgery
December 22, 2010 – Laura Beil
Editor's Page
December 22, 2010 – Debu Tripathy, MD
New Drugs, New Direction
January 05, 2011 – Elaine Schattner, MD

Guiding the Use of Partial-Breast Radiation

The controversy over the use of accelerated partial-breast radiation (APBI) is reflected in the recommendations from the professional organizations that oversee radiation oncology and surgery.

BY Kathy LaTour
PUBLISHED December 22, 2010

The controversy over the use of accelerated partial-breast radiation (APBI) is reflected in the recommendations from the professional organizations that oversee radiation oncology and surgery.

The American Society for Radiation Oncology (ASTRO) issued its first-ever consensus statement in 2009 to provide guidance regarding the use of APBI outside of a clinical trial and to serve as a framework to promote additional clinical investigations into the optimal role of APBI in the treatment of breast cancer. The guidelines, which were written for clinicians, indicate that “conservative patient-selection criteria” be followed. Specifically, the guidelines offer a long list of criteria but exclude women with ductal carcinoma in situ (DCIS) and those who show multicentricity or multiple locations of tumor.

Those suitable, according to the guidelines, include women over the age of 60 with tumors smaller than 2 centimeters, pathologically negative nodes and positive estrogen-receptor status.

The American Society of Breast Surgeons has indicated that APBI can be used for women aged 45 and older who have either invasive or DCIS disease, tumors 3 centimeters or less with negative margins and a negative sentinel lymph node.

Both organizations recommend patients discuss the risk and benefit of the treatment with their radiation oncologist. The guidelines will certainly evolve as more data comes in.

Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Breast Cancer CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In